Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28417961 | 0.94 | CA12 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28415126 | 0.94 | CA12 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2955338 | 0.94 | CA12 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8498288 | 0.92 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8499444 | 0.92 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3421954 | 0.92 | CA12 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8495268 | 0.92 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28905825 | 0.92 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2954535 | 0.92 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL19371460 | 0.90 | CA12 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102725264-A | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | HANALL BIOPHARMA CO LTD | 2012-10-10 | — | — | CN | claimed |
| US-10272055-B2 | Therapeutic compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| CN-102725264-B | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | HANALL BIOPHARMA CO LTD | 2014-12-17 | — | — | CN | disclosed |
| CN-102725264-A | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient | HANALL BIOPHARMA CO LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-101263256-B | Amphoteric stilbene composition | HEWLETT PACKARD DEVELOPMENT CO | 2011-07-06 | — | — | CN | disclosed |
| WO-2004009869-A2 | CORROSION-INHIBITING COATING FOR METAL SURFACES | UNIVERSITY OF DAYTON (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040016363-A1 | CORROSION-INHIBITING COATING | VENTURE LENDING & LEASING, IV, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| CN-1460472-A | Biquanide vanadium complex plaster preparation for curing diabetes and its application | YUE YI (CN) | 2003-12-10 | — | — | CN | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | G6PD, BRCA1, BPGM | GRIN2D 3378/4885GRIN3B 558/4885GRIN1 1422/4885 |
| US-10272055-B2 | Therapeutic compounds and methods | G6PD, BRCA1, BPGM | GRIN2D 3378/4885GRIN3B 558/4885GRIN1 1422/4885 |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | EPHX1, EPHX2, CYP4X1 | GRIN2D 4537/4885GRIN3B 4267/4885GRIN1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.